Efficacy of Addition of Atomoxetine to Speech Therapy in Stuttering Severity of Children Aged 4-12 Years A Double-Blind Randomized Controlled Trial

被引:0
|
作者
Ahmadabadi, Farzad [1 ,2 ]
Motamedi, Ahdullah [3 ]
Zahed, Ghazal [2 ]
Motamedi, Akram [4 ]
Shahriari, Farshid [5 ]
Pourfarzi, Farhad [6 ]
Jafari, Narjes [1 ]
Hosseini, Mohammad Mehdi [4 ]
机构
[1] Shahid Beheshti Univ Med Sci, Pediat Neurol Res Ctr Excellence, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Fac Med, Mofid Childrens Hosp, Pediat Neurol Dept, Tehran, Iran
[3] Allameh Tabatabai Univ, Dept Clin Psychol, Tehran, Iran
[4] Ardabil Univ Med Sci, Fac Med, Pediat, Ardebil, Iran
[5] Ardabil Univ Med Sci, Fatemi Hosp, Dept Psychiat, Ardebil, Iran
[6] Ardabil Univ Med Sci, Digest Recearch Ctr, Ardebil, Iran
关键词
Stuttering; Speech Therapy; Atomoxetine; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; ADOLESCENTS; LANGUAGE; ANXIETY; ADULTS;
D O I
10.22037/ijcn.v16i3.34450
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives Stuttering is a comon problem at all ages that is required to be treated since childhood. Atomoxetine is currently used for the treatment of attention deficit hyperactivity disorder (ADHD). It can be effective for the treatment of stuttering due to its selective inhibition of norepinephrine reuptake and dopaminergic properties. Therefore, this randomized controlled trial aimed to evaluate the effect of atomoxetine on children's stuttering. Materials & Methods The children aged 4-12 years and diagnosed with stuttering, referred to Pediatric Neurology and Psychology clinics , were randomly divided into experimental (n=50) and control (n=50) groups. One group received atomoxetine plus speech therapy, and the other group received only speech therapy. Both groups completed the Stuttering Severity Instrument-Fourth Edition at the baseline (on the first visit) and 3 months after the intervention. The results were compared between the two groups using SPSS software (version 21). Results Most of the children (67%) were male. Moreover, 24%, 46%, and 30% of the subjects were within the age ranges of < 60, 60-95, and > 95 months, respectively. Nearly half of the patients (52%) had a positive family history of stuttering. Stuttering severity was the highest within the age range of 60-95 months, in left-handed children, in those who used formula, and in those who felt insecure in the family; however, there was no difference in stuttering severity based on child's gender, concomitant ADHD, multilingualism, facial or movement tics, sleeping hours, and using teats. The mean stuttering severity reduced in both groups (P<0.001), with a greater decrease in the experimental group, compared to that of the control group (P=0.011). Conclusion Atomoxetine plus speech therapy is effective for the treatment of children's stuttering and can be used as a complementary treatment strategy in such patients.
引用
收藏
页码:47 / 56
页数:10
相关论文
共 50 条
  • [1] Assessment the Efficacy of Atomoxetine in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Trial
    Eslamzadeh, Mahbobeh
    Hebrani, Paria
    Behdani, Fatemeh
    Moghadam, Malihee Dadgar
    Panaghi, Leili
    Mirzadeh, Mansoureh
    Arabgol, Fariba
    IRANIAN JOURNAL OF PSYCHIATRY AND BEHAVIORAL SCIENCES, 2018, 12 (02)
  • [2] Efficacy of Probiotic Therapy on Atopic Dermatitis in Children: A Randomized, Double-blind, Placebo-controlled Trial
    Yang, Hyeon-Jong
    Min, Taek Ki
    Lee, Hae Won
    Pyun, Bok Yang
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2014, 6 (03) : 208 - 215
  • [3] Effect of L. reuteri on bowel movements in children aged 6 months to 4 years: A double-blind randomized controlled trial
    Jung, Camille
    Kalach, Nicolas
    Degas, Vanessa
    Jeridi, Yasmine
    Bertrand, Valerie
    Bellaiche, Marc
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [4] Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial
    Ghaleiha, Ali
    Ghyasvand, Mohammad
    Mohammadi, Mohammad-Reza
    Farokhnia, Mehdi
    Yadegari, Noorollah
    Tabrizi, Mina
    Hajiaghaee, Reza
    Yekehtaz, Habibeh
    Akhondzadeh, Shahin
    JOURNAL OF PSYCHOPHARMACOLOGY, 2014, 28 (07) : 677 - 685
  • [5] A double-blind randomized controlled trial of toremifen therapy for mastalgia
    Gong, C
    Song, EW
    Jia, WJ
    Qin, L
    Guo, JJ
    Jia, HX
    Hu, XQ
    Su, FX
    ARCHIVES OF SURGERY, 2006, 141 (01) : 43 - 47
  • [6] Randomized, Double-Blind, Placebo-Controlled Trial of Herbal Therapy for Children with Asthma
    Wong, Eliza L. Y.
    Sung, Rita Yn Tz
    Leung, Ting Fan
    Wong, Yeuk Oi
    Li, Albert M. C.
    Cheung, Kam Lau
    Wong, Chun Kwok
    Fok, Tai Fai
    Leung, Ping Chung
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2009, 15 (10) : 1091 - 1097
  • [7] Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial
    Mwesigwa, Naome
    Vernetti, Patricio Millar
    Kirabo, Annet
    Black, Bonnie
    Ding, Tan
    Martinez, Jose
    Palma, Jose-Alberto
    Biaggioni, Italo
    Kaufmann, Horacio
    Shibao, Cyndya A.
    CLINICAL AUTONOMIC RESEARCH, 2024, 34 (06) : 561 - 569
  • [8] A randomized controlled double-blind trial of the efficacy of sufentanil addition to ropivacaine epidural anesthesia for cesarean section
    Heesen, M
    ANESTHESIOLOGY, 2005, 102 (05) : A41 - A41
  • [9] Efficacy and safety of statin therapy in children with familial hypercholesterolemia -: A randomized, double-blind, placebo-controlled trial with simvastatin
    de Jongh, S
    Ose, L
    Szamosi, T
    Gagné, C
    Lambert, M
    Scott, R
    Perron, P
    Dobbelaere, D
    Saborio, M
    Tuohy, MB
    Stepanavage, M
    Sapre, A
    Gumbiner, B
    Mercuri, M
    van Trotsenburg, ASP
    Bakker, HD
    Kastelein, JJP
    CIRCULATION, 2002, 106 (17) : 2231 - 2237
  • [10] Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study
    Michelson, D.
    Adler, L. A.
    Amsterdam, J. D.
    Dunner, D. L.
    Nierenberg, A. A.
    Reimherr, F. W.
    Schatzberg, A. F.
    Kelsey, D. K.
    Feldman, P. D.
    Levine, L. R.
    Williams, D. W.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S290 - S291